Cystic fibrosis: bacterial pathogenesis and CFTR (cystic fibrosis transmembrane conductance regulator) modulators

被引:0
|
作者
Vargas-Roldan, Silvia Y. [1 ,2 ]
Lezana-Fernandez, Jose L. [3 ,4 ]
Cerna-Cortes, Jorge F. [2 ]
Partida-Sanchez, Santiago [5 ,6 ]
Santos-Preciado, Jose, I [1 ]
Rosales-Reyes, Roberto [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Fac Med, Unidad Invest Med Expt, Ciudad De Mexico, Mexico
[2] Inst Politecn Nacl, Dept Microbiol, Lab Microbiol Mol, Escuela Nacl Ciencias Biol, Ciudad De Mexico, Mexico
[3] Hosp Infantil Mexico Dr Federico Gomez, Lab Fisiol Respiratoria & Clin Fibrosis Quist, Ciudad De Mexico, Mexico
[4] Assoc Mexicana Fibrosis Quist, Direcc Med, Ciudad De Mexico, Mexico
[5] Nationwide Childrens Hosp, Ctr Microbial Pathogenesis, Abigail Wexner Res Inst, Columbus, OH USA
[6] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA
来源
BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO | 2022年 / 79卷 / 04期
关键词
Cystic fibrosis; Pseudomonas aeruginosa; Burkholderia cenocepacia; CFTR modulators; VI SECRETION SYSTEM; PSEUDOMONAS-AERUGINOSA; ADAPTATION; POTENTIATOR; IVACAFTOR;
D O I
10.24875/BMHIM.21000128
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Cystic fibrosis is an autosomal recessive inherited disease caused by mutations in the cystic fibrosis transmembrane con-ductance regulator gene (CFTR). CFTR is a protein that transports ions across the membrane of lung epithelial cells. Loss of its function leads to the production of thick sticky mucus, where various bacterial pathogens can establish and adapt, contributing to the gradual loss of lung function. In this review, evidence of the molecular mechanisms used by Pseudomonas aeruginosa and Burkholderia cenocepacia to survive and persist in the pulmonary environment will be provided. Additionally, new therapeutic strategies based on CFTR function modulators will be described.
引用
收藏
页码:215 / 221
页数:7
相关论文
共 50 条
  • [1] Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis
    Derichs, Nico
    EUROPEAN RESPIRATORY REVIEW, 2013, 22 (127) : 58 - 65
  • [2] Cystic Fibrosis Transmembrane Conductance Regulator Modulators: The End of the Beginning
    Barry, Peter J.
    Ronan, Nicola
    Plant, Barry J.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 36 (02) : 287 - 298
  • [3] Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function
    Shuzhong Zhang
    Chandra L. Shrestha
    Benjamin T. Kopp
    Scientific Reports, 8
  • [4] The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis
    Sergeev, Valentine
    Chou, Frank Y.
    Lam, Grace Y.
    Hamilton, Christopher Michael
    Wilcox, Pearce G.
    Quon, Bradley S.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (02) : 147 - 154
  • [6] Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
    Edmondson, Claire
    Course, Christopher William
    Doull, Iolo
    ARCHIVES OF DISEASE IN CHILDHOOD, 2021, 106 (10) : 941 - 945
  • [7] Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis
    Burgener, Elizabeth B.
    Moss, Richard B.
    CURRENT OPINION IN PEDIATRICS, 2018, 30 (03) : 372 - 377
  • [8] Tritherapy with cystic fibrosis transmembrane conductance regulator protein modulators in cystic fibrosis
    Colodro, Oscar Fielbaum
    Grell, Alberto Vidal
    Yarur, Alejandra Mendez
    Clerc, Camila Sobarzo
    ANDES PEDIATRICA, 2022, 93 (06): : 898 - 905
  • [9] Combating Cystic Fibrosis: In Search for CF Transmembrane Conductance Regulator (CFTR) Modulators
    Noy, Efrat
    Senderowitz, Hanoch
    CHEMMEDCHEM, 2011, 6 (02) : 243 - 251
  • [10] The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
    Meng, Xin
    Clews, Jack
    Kargas, Vasileios
    Wang, Xiaomeng
    Ford, Robert C.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (01) : 23 - 38